Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 9/20 | 0.38 |
| ▸ | CPT2 | P23786 | 7/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836916 | 0.92 | USP30 (0.37) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL24926173 | 0.92 | USP30 (0.37) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL27167595 | 0.91 | CPT1A (0.40) | CPT1ACPT2CPT1BESR1 | |
| SCHEMBL27167598 | 0.91 | CPT1A (0.40) | CPT1ACPT2CPT1BESR1 | |
| SCHEMBL21070364 | 0.91 | CPT1A (0.36) | CPT1ACPT2CPT1B | |
| SCHEMBL27167593 | 0.91 | CPT1A (0.40) | CPT1ACPT2CPT1BESR1 | |
| SCHEMBL21070360 | 0.91 | CPT1A (0.36) | CPT1ACPT2CPT1B | |
| SCHEMBL21070458 | 0.91 | ESR1 (0.36) | CPT1ACPT2CPT1BADAM17ESR1 | |
| SCHEMBL23884177 | 0.91 | ESR1 (0.36) | CPT1ACPT2CPT1BADAM17ESR1 | |
| SCHEMBL21070456 | 0.91 | ESR1 (0.36) | CPT1ACPT2CPT1BADAM17ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |